Posterior Reversible Encephalopathy Syndrome (PRES) Associated With Lenvatinib: A Disproportionality Analysis

Journal of Pharmacy Technology · Published 2026-04-30 · DOI 10.1177/87551225261446468

Free full text

Authors being retrieved — see the publisher record. https://doi.org/10.1177/87551225261446468

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Related articles

• Nirmatrelvir-Ritonavir Versus Short-Course Remdesivir for Mild COVID-19 in High-Risk Hospitalized Patients: A Propensity Score-Matched Study · Journal of Pharmacy Technology · 2026 · Same journal
• Restriction Evaluation of Appropriate Carbapenem Therapy (REACT): A Multisite Observational Study · Journal of Pharmacy Technology · 2026 · Same journal
• Impact of Methicillin-Resistant Staphylococcus aureus Nasal PCR Versus Culture on Vancomycin Utilization in Pneumonia Management · Journal of Pharmacy Technology · 2025 · Same journal
• Time to Vancomycin De-Escalation in Pneumonia Patients Screened for MRSA Using Culture vs PCR Testing · Journal of Pharmacy Technology · 2026 · Same journal
• Impact of an Interruptive Alert on the Number of Women Receiving CDC-Recommended Therapy for Trichomoniasis · Journal of Pharmacy Technology · 2025 · Same journal
• Evaluation of Neuropsychiatric Events in Patients Receiving Levetiracetam for Seizure Prophylaxis Following Traumatic Brain Injury · Journal of Pharmacy Technology · 2026 · Same journal
• Overview of Diabetes Medications: Traditional and New-Generation Agents and Their Off-Label Use for Weight Loss · Journal of Pharmacy Technology · 2026 · Same journal
• Emergency Drug Box Accuracy: Analysis of Manual Replenishment Errors and the Use of RFID as a Preventative Strategy · Journal of Pharmacy Technology · 2025 · Same journal
• Vancomycin Overdose and Infusion Rate Error Leading to a Mixed Anticholinergic-Type Syndrome in a Hemodialysis Patient: A Case Report · Journal of Pharmacy Technology · 2026 · Same journal
• Signals of Toxicity Associated With Gene Therapy: The Case of Etranacogene Dezaparvovec in the Treatment of Hemophilia B · Journal of Pharmacy Technology · 2026 · Same journal